Editor's Note: Overall Survival was reached in the phase 3 trial and favored Imbruvica.

Pharmacyclics (UNKNOWN:PCYC.DL) and Johnson & Johnson's (NYSE:JNJ) Imbruvica has had a great roll-out thus far.

And the celebration may not be over yet. 

New data indicate that Imbruvica embarrassed the competition, GlaxoSmithKline's (NYSE:GSK) Arzerra. Imbruvica was associated with almost an 80% decline in the risk of cancer progression or death compared to Arzerra in a head-to-head phase 3 trial. And the safety profiles of the drugs were fairly similar.

But, there are some threats on the horizon, including AbbVie's (NYSE:ABBV) ABT-199.

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the data and what investors need to know about Imbruvica.

David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.